New vaccine targets aggressive brain tumors in early trial

This early-phase study tests a personalized DNA vaccine designed to target unique markers on a person's glioblastoma (a fast-growing brain cancer). The vaccine is given along with an immunotherapy drug (retifanlimab) that helps the immune system attack the tumor. The study includes 27 adults with newly diagnosed, unmethylated glioblastoma and focuses on safety and whether the vaccine triggers an immune response. This is not a cure, but a step toward better control of this aggressive disease.